Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 03 Feb 2020

The emergence of a novel coronavirus (preliminarily referred to as 2019-nCoV) has taken hold of public attention in the last month. MIMS Doctor speaks to Professor Dale Fisher, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, to get a better picture of the situation and steps being undertaken in Singapore to prevent spread of the virus.

Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients possible.
Jairia Dela Cruz, 31 Jan 2020
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.

Eczema with allergic sensitization at 1 year predictive of childhood asthma, food allergy

Pearl Toh
27 Dec 2017

The presence of eczema or atopic dermatitis with concurrent allergic sensitization at 1 year of age was associated with an increased risk of developing asthma and food allergy in later childhood at 3 years old, according to the CHILD* study.

“Our findings are useful to help predict which children may develop asthma and allergies,” said lead author Maxwell Tran from McMaster University in Hamilton, Canada, who noted that although the filaggrin (FLG) gene variants are known risk factors for allergy, FLG genotyping is costly and not commonly used in clinical practice. “[T]his research offers healthcare professionals an alternative method of identifying at-risk children.”

The multicentre longitudinal cohort study included 2,311 children who completed skin prick testing at 1 year old, of which those who produced a ≥2 mm than that produced by the negative control to any of the 10 food or inhalant allergens were considered “sensitized”. They were assessed again at 3 years of age for asthma, food allergy, allergic rhinitis, and atopic dermatitis. [J Allergy Clin Immunol 2017;doi:10.1016/j.jaci.2017.08.024]

Children with atopic dermatitis who were sensitized to an allergen tested at 1 year old were sevenfold more likely to develop asthma by age 3 years compared with the reference group of children without atopic dermatitis who were not sensitized (adjusted relative risk [RR], 7.04, 95 percent confidence interval [CI], 4.13–11.99).

When assessed by the source of sensitization, food sensitization, but not inhalant sensitization, appeared to enhance the association between atopic dermatitis at age 1 year and asthma development at age 3 years.

However, children with atopic dermatitis but were not sensitized to any allergen tested at age 1 year did not have a higher risk of developing asthma at age 3 years compared with the nonsensitized reference without atopic dermatitis (RR, 0.46, 95 percent CI, 0.11–1.93).

Similarly, the presence of atopic dermatitis with concurrent sensitization at 1 year old was associated with a significantly higher risk of food allergy (RR, 33.79, 95 percent CI, 18.89–60.47) and allergic rhinitis at 3 years old (RR, 11.75, 95 percent CI, 5.73–24.12).

“Much of what happens to us later in life is related to the exposures we encounter in early childhood,” said study principal investigator Dr Malcolm Sears, a professor of medicine at McMaster University.

“A potential explanation [for the enhanced association between atopic dermatitis and food allergy in sensitized children] is that children shown to be sensitized to food allergens at age 1 year who also had atopic dermatitis might have consequently avoided the foods to which they were sensitized,” said Sears and co-authors, who believed that avoidance of or delayed exposure to certain food were associated with increased risk of food sensitization. [Pediatr Allergy Immunol 2017;28:471-477]  

“Children with atopic dermatitis and evidence of sensitization to common food or inhalant allergens as early as age 1 year represent a high-risk subgroup that warrants further examination in primary intervention studies,” they added.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 03 Feb 2020

The emergence of a novel coronavirus (preliminarily referred to as 2019-nCoV) has taken hold of public attention in the last month. MIMS Doctor speaks to Professor Dale Fisher, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, to get a better picture of the situation and steps being undertaken in Singapore to prevent spread of the virus.

Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients possible.
Jairia Dela Cruz, 31 Jan 2020
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.